Stage-Specific Action of Matrix Metalloproteinases Influences Progressive Hereditary Kidney Disease
2006
Understanding Alport Syndrome and Potential Treatments
publication
Evidence: moderate
Author Information
Author(s): Raghu Kalluri, Michael Zeisberg
Hypothesis
Does the failure to switch collagen isoforms in Alport syndrome make the glomerular basement membrane more susceptible to degradation by matrix metalloproteinases?
Conclusion
MMP inhibitors may delay disease progression in early stages of Alport syndrome but could worsen outcomes if used later.
Supporting Evidence
- Alport syndrome affects one in 50,000 live births in the U.S.
- The GBM in Alport syndrome is more susceptible to degradation by MMPs.
- MMP inhibitors delayed disease progression in early-stage mice.
Takeaway
Alport syndrome is a kidney disease that can get worse over time, but some medicines might help if given early.
Methodology
The study used a mouse model lacking functional α3(IV) collagen to investigate the role of MMPs in disease progression.
Limitations
The findings are based on animal models, which may not fully translate to human patients.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website